Keybanc Maintains Overweight on Netstreit, Raises Price Target to $27

Keybanc maintains Netstreit (NYSE:NTST) with a Overweight and raises the price target from $23 to $27.

byBenzinga Newsdesk

July 15, 2021

1 minute read

Keybanc maintains Netstreit (NYSE:NTST) with a Overweight and raises the price target from $23 to $27.

Morgan Stanley Maintains Equal-Weight on Rapid7, Raises Price Target to $106

By Benzinga Newsdesk

Today, 5:19 AM

Morgan Stanley maintains Rapid7 (NASDAQ:RPD) with a Equal-Weight and raises the price target from $97 to $106.

RPD

News

Roman DBDR Tech Acquisition Corp. SPAC Merger Partner CompoSecure Reports Partnership With Oxygen To Offer Cards For Oxygen Elements, No Terms Disclosed

By Benzinga Newsdesk

Today, 5:19 AM

The new Oxygen Elements debit card offers four unique levels of rewards for consumers SOMERSET, N.J.--(BUSINESS WIRE)-- CompoSecure Holdings, L.L.C. (“CompoSecure”), a leading provider of premium financial

DBDR

Democrats Wants New President Candidate In 2024: Here’s Why They’re Souring On Joe Biden (And It’s Not Inflation)

By Chris Katje

Today, 5:19 AM

A new poll shows that Americans may be seeking out a new president in the 2024 election. Here’s how President Joe Biden fared in the poll and what the key reason was people may want a change.

NYT

Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab

By Vandana Singh

Today, 5:19 AM

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) and Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd., a subsidiary of Huadong Medicine Co., Ltd., have announced a strategic collaboration to develop and commercialize Kiniksa's Arcalyst and mavrilimumab in the Asia Pacific Region.

KNSA

Keybanc Maintains Overweight on Netstreit, Raises Price Target to $27

Related Posts

Morgan Stanley Maintains Equal-Weight on Rapid7, Raises Price Target to $106

Roman DBDR Tech Acquisition Corp. SPAC Merger Partner CompoSecure Reports Partnership With Oxygen To Offer Cards For Oxygen Elements, No Terms Disclosed

Democrats Wants New President Candidate In 2024: Here’s Why They’re Souring On Joe Biden (And It’s Not Inflation)

Kiniksa Pharma, Huadong Medicine Ink Licensing Pact For Arcalyst, Mavrilimumab